Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.91 USD | +7.62% | +4.91% | +17.19% |
05-14 | Oppenheimer Cuts Fulcrum Therapeutics Price Target to $14 From $16, Maintains Outperform Rating | MT |
05-14 | Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target is $15 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.19% | 492M | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+47.13% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- FULC Stock
- News Fulcrum Therapeutics, Inc.
- Stifel Upgrades Fulcrum Therapeutics to Buy From Hold, Raises Price Target to $11 From $4